Multiple Myeloma 2000. Multicentric Evaluation of a Therapeutic Strategy Optimized in Multiple Myeloma. Analysis of Efficiency and Possible Pronostic Impact of Minimal Residual Disease (Measured By PCR And Citometry of Flow) in Patients With Complete Response
Phase 3
N/A
69 Years
N/A
69 Years
Not Enrolling
Both
Multiple Myeloma
Both
Multiple Myeloma
Trial Information
Multiple Myeloma 2000. Multicentric Evaluation of a Therapeutic Strategy Optimized in Multiple Myeloma. Analysis of Efficiency and Possible Pronostic Impact of Minimal Residual Disease (Measured By PCR And Citometry of Flow) in Patients With Complete Response
Inclusion Criteria:
- Less 70 years
- ECOG 0-2
- Symptomatic MM (pain, anemia, infection, haemorrhage, loss of weight, hypercalcemia,
extramedulary plasmocytoma, creatinine >2 mg/dl).
- No previous chemotherapy
Exclusion Criteria:
- >70 years
- ECOG 3-4
- myeloma quiescent
- cardiopathy
- liver disfunction
- HIV+
- Hepatitis B-C +
- Previous chemotherapy
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Principal Investigator
Joan Bladé, Dr
Investigator Role:
Study Chair
Investigator Affiliation:
Hospital Clinic Barcelona
Authority:
Spain: Ministry of Health
Study ID:
PETHEMA MM-2000
NCT ID:
NCT00560053
Start Date:
January 2000
Completion Date:
February 2005
Related Keywords:
- Multiple Myeloma
- Multiple Myeloma
- Alternating chemotherapy
- Transplantation
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Neoplasm, Residual
Name | Location |
|---|
